Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz H2 Launch Ramp-Up Begins With A US First

Novartis Subsidiary Launches High Dose Intravenous Iron, Ferumoxytol Injection

Executive Summary

Sandoz has kicked off what promises to be a busy second half of 2021 in terms of launches for the Novartis subsidiary, introducing the first US generic of the Feraheme feumoxytol injectable treatment for iron deficiency anemia.

You may also be interested in...



‘Challenging’ Times For Sandoz As COVID Bites

Sandoz saw both its sales and core operating profit experience double-digit drops in what management described as a “challenging” first quarter of 2021. However, its performance is expected to stabilize in the back end of the year as pandemic-related pressures ease.

Biosimilars Boost Offsets Generics Slide For Sandoz

Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.

What Aspects Will Give Humira Biosimilars The Edge In 2023?

With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel